Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131744 | 0.81 | LMNA (0.51) | CNR1MEN1KMT2ALMNAHTR6 | |
| SCHEMBL13201394 | 0.68 | ALDH1A1 (0.45) | CNR1KMT2ALMNAALDH1A1 | |
| SCHEMBL3970286 | 0.67 | CNR1 (0.36) | CNR1HTR6MMP2MMP9 | |
| SCHEMBL6853497 | 0.66 | MMP2 (0.40) | MEN1KMT2ALMNAHTR6MMP2 | |
| SCHEMBL3968265 | 0.66 | CNR1 (0.39) | CNR1HTR6ALDH1A1MMP2MMP9 | |
| SCHEMBL20134878 | 0.64 | LMNA (0.53) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL542561 | 0.64 | LMNA (0.53) | MEN1KMT2ALMNATNKSALDH1A1 | |
| SCHEMBL17570773 | 0.63 | LMNA (0.51) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL6135313 | 0.63 | LMNA (0.51) | CNR1MEN1KMT2ALMNAHTR6 | |
| SCHEMBL542817 | 0.63 | LMNA (0.51) | MEN1KMT2ALMNAHTR6TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | CNR1 1621/4885MEN1 1882/4885KMT2A 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.